ABL1 and cancer: In our HC-NPs, we combined the specific anticancer activity of IM that binds specifically to the BCR-ABL oncoprotein present only in the CML cells, and the anticancer property of AgNPs, thanks to the production of ROS, in order to improve their efficacy on cancer cells only.